The Russian government is considering changing the mechanism of setting prices for essential drugs in Russia, which foreign drugmakers fear will create administrative barriers.
According to DSM Group, one of Russia’s leading analytic agencies in the field of pharmaceuticals, at present essential drugs account for 31.1% of the overall Russian pharmaceutical market, with their prices regulated by the state.
According to the current scheme, the Ministry of Health registers maximum sale prices for drugs in Russia in coordination with the Federal Tariff Service, while regions set wholesale and retail markups.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze